RT Journal Article
T1 Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial.
A1 Perez-Sanchez, Carlos
A1 Aguirre, Maria Angeles
A1 Ruiz-Limon, Patricia
A1 Abalos-Aguilera, Maria Carmen
A1 Jimenez-Gomez, Yolanda
A1 Arias-de la Rosa, Ivan
A1 Rodriguez-Ariza, Antonio
A1 Fernandez-Del Rio, Lucia
A1 Gonzalez-Reyes, Jose Antonio
A1 Segui, Pedro
A1 Collantes-Estevez, Eduardo
A1 Barbarroja, Nuria
A1 Velasco, Francisco
A1 Sciascia, Savino
A1 Cecchi, Irene
A1 Cuadrado, Maria Jose
A1 Villalba, Jose Manuel
A1 Lopez-Pedrera, Chary
K1 Antiphospholipid syndrome
K1 Extracellular traps
K1 Inflammation
K1 Oxidative stress
K1 Thrombosis
K1 Ubiquinol
AB Antiphospholipid syndrome (APS) leukocytes exhibit an oxidative perturbation, directly linked to alterations in mitochondrial dynamics and metabolism. This disturbance is related to the patients' prothrombotic status and can be prevented by in vitro treatment with coenzyme Q10. Our aim was to investigate short-term effects of in vivo ubiquinol (reduced coenzyme Q10 [Qred]) supplementation on markers related to inflammation and thrombosis in APS through a prospective, randomized, crossover, placebo-controlled trial. Thirty-six patients with APS were randomized to receive Qred (200 mg/d) or placebo for 1 month. Thirty-three patients with APS completed the intervention, which increased plasma coenzyme Q10. Qred improved endothelial function and decreased monocyte expression of prothrombotic and proinflammatory mediators, inhibited phosphorylation of thrombosis-related protein kinases, and decreased peroxides and percentage of monocytes with depolarized mitochondria; mitochondrial size was increased, and mitochondrial biogenesis-related genes were upregulated. Qred ameliorated extruded neutrophil extracellular traps in neutrophils and downregulated peroxides, intracellular elastase, and myeloperoxidase. Nanostring microRNA profiling revealed 20 microRNAs reduced in APS monocytes, and 16 of them, with a preponderance of cardiovascular disease-related target mRNAs, were upregulated. Monocytes gene profiling showed differential expression of 29 atherosclerosis-related genes, 23 of them changed by Qred. Interaction networks of genes and microRNAs were identified. Correlation studies demonstrated co-ordinated effects of Qred on thrombosis and endothelial function-associated molecules. Our results highlight the potential of Qred to modulate the overexpression of inflammatory and thrombotic risk markers in APS. Because of the absence of clinically significant side effects and its potential therapeutic benefits, Qred might act as safe adjunct to standard therapies in APS. 
PB Lippincott Williams & Wilkins
YR 2017
FD 2017-06-26
LK http://hdl.handle.net/10668/11382
UL http://hdl.handle.net/10668/11382
LA en
NO Pérez-Sánchez C, Aguirre MÁ, Ruiz-Limón P, Ábalos-Aguilera MC, Jiménez-Gómez Y, Arias-de la Rosa I, et al. Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile: A Randomized, Placebo-Controlled Trial. Arterioscler Thromb Vasc Biol. 2017 Oct;37(10):1923-1932
DS RISalud
RD Apr 19, 2025